The American Journal of Managed Care

Lower Risk of Recurrent Clostridioides difficile Infections Shown Over Past Decade

A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program. Risk of recurrent ...
EurekAlert!

Clostridioides difficile infection: a review of emerging practices for infection treatment and prevention of recurrence

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...
The American Journal of Managed Care

FMT Is Cost Effective for Any Recurrent Clostridioides Difficile Infection, Study Says

Research found fecal microbiota transplantation (FMT) to be an optimal cost-effective treatment strategy for first and subsequent recurrent Clostridioides difficile infection (CDI), challenging ...
Medical Dialogues

4-week Vancomycin pulse and taper regimen reduces C. difficile recurrence, finds study

A new study published in the Journal of the American Medical Association revealed that a 4-week vancomycin pulse and taper ...
Healio

4-week vancomycin pulse-taper regimen may postpone, prevent C. difficile recurrence

A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent Clostridioides difficile ...
Business Wire

Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (fecal microbiota, live – jslm) in a Real-World Patient Population with Comorbidities and Risk ...

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff ...
Monthly Prescribing Reference

Ridinilazole Reduces C difficile Infection Recurrence More Effectively Than Vancomycin

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...
MedPage Today

Oral Microbiome Therapy for Recurrent C. Diff Mostly Holds Up at 6 Months

WASHINGTON -- Extended follow-up of a phase III trial demonstrated continued benefit for an investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infections.
MarketWatch

Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol ...

Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that the independent Data Monitoring ...
Yahoo Finance

Crestone Announces Positive Data from Phase 2 Clinical Trial of CRS3123 for C. difficile Infections Published in The Lancet Infectious Diseases

BOULDER, Colo., March 09, 2026--(BUSINESS WIRE)--Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive ...
MarketWatch

Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in the 7MM during the Forecast Period (2025-2034)

The MarketWatch News Department was not involved in the creation of this content. The Clostridioides difficile infection market is predicted to boost mainly owing to an increased aging population, ...